Jonathan Barratt

Oct 30, 2024 | consultantlive.com | Jonathan Barratt

Understanding Recent Updates in IgA Nephropathy Pipeline - Episode 1Published on: In this segment, Barratt reflects on recent updates in the management of IgA nephropathy. The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of the several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline.

Oct 30, 2024 | hcplive.com | Jonathan Barratt

NewsVideoOctober 30, 2024Author(s):In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan. The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of the several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline.

Oct 30, 2024 | hcplive.com | Jonathan Barratt

The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline. Now, with multiple fully approved therapies, the prognosis for patients is brighter than at any point in history.

Oct 30, 2024 | consultantlive.com | Jonathan Barratt

In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN. The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of the several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline.

Oct 30, 2024 | hcplive.com | Jonathan Barratt

The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of the several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline. Now, with multiple fully approved therapies, the prognosis for patients is brighter than at any point in history. In this video, which is the third in a 5-part series, Barratt discusses data from the phase 2 IGNAZ study.